Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.52 |
| ▸ | USP2 | O75604 | 1/20 | 0.52 |
| ▸ | POLB | P06746 | 1/20 | 0.52 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.52 |
| ▸ | P2RY2 | P41231 | 7/20 | 0.45 |
| ▸ | P2RY12 | Q9H244 | 3/20 | 0.44 |
| ▸ | SLC28A1 | O00337 | 1/20 | 0.44 |
| ▸ | SLC28A2 | O43868 | 1/20 | 0.44 |
| ▸ | SLC29A1 | Q99808 | 1/20 | 0.44 |
| ▸ | SLC28A3 | Q9HAS3 | 1/20 | 0.44 |
| ▸ | GAPDH | P04406 | 1/20 | 0.42 |
| ▸ | P2RY14 | Q15391 | 2/20 | 0.41 |
| ▸ | P2RY4 | P51582 | 1/20 | 0.41 |
| ▸ | P2RY6 | Q15077 | 4/20 | 0.41 |
| ▸ | RNASE1 | P07998 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30574184 | 0.92 | MEN1 (0.52) | MEN1USP2POLBKMT2AP2RY2 | |
| SCHEMBL2623802 | 0.92 | MEN1 (0.55) | MEN1USP2POLBKMT2AP2RY2 | |
| SCHEMBL9135379 | 0.91 | MEN1 (0.64) | MEN1USP2POLBKMT2AP2RY2 | |
| SCHEMBL25504929 | 0.89 | MEN1 (0.51) | MEN1USP2POLBKMT2AP2RY2 | |
| SCHEMBL26502632 | 0.89 | P2RY2 (0.53) | MEN1USP2POLBKMT2AP2RY2 | |
| SCHEMBL16904879 | 0.89 | MEN1 (0.51) | MEN1USP2POLBKMT2AP2RY2 | |
| SCHEMBL26502697 | 0.89 | P2RY2 (0.53) | MEN1USP2POLBKMT2AP2RY2 | |
| SCHEMBL2623813 | 0.89 | SLC28A1 (0.53) | MEN1USP2POLBKMT2AP2RY2 | |
| SCHEMBL25504874 | 0.89 | MEN1 (0.51) | MEN1USP2POLBKMT2AP2RY2 | |
| SCHEMBL25504886 | 0.89 | MEN1 (0.51) | MEN1USP2POLBKMT2AP2RY2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12037586-B2 | 4′-phosphate analogs and oligonucleotides comprising the same | DICERNA PHARMACEUTICALS, INC. (US) | 2024-07-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12037586-B2 | 4′-phosphate analogs and oligonucleotides comprising the same | RNGTT, DERA, MTAP | MEN1 4146/4885USP2 4395/4885POLB 137/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.